Latest & greatest articles for testosterone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on testosterone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on testosterone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for testosterone

1. What is the role of free testosterone testing in the workup of suspected male hypogonadism?

What is the role of free testosterone testing in the workup of suspected male hypogonadism? Chiefs’ Inquiry Corner – 9/16/19 – Clinical Correlations Search Chiefs’ Inquiry Corner – 9/16/19 September 16, 2019 2 min read Free testosterone is generally not needed in the workup of male hypogonadism, as total testosterone is generally a good proxy, and a more reliable test (with some caveats- see below!). One exception to this rule is in patients with a suspected sex hormone binding globulin (...) deficiency (as in the case of obesity, type 2 diabetes or steroid exposure), in whom total testosterone can be low while the free fraction remains normal. If measuring free testosterone, be aware that the most commonly used assay, the direct immunoassay (or analog assay), is notoriously unreliable. Instead, order free testosterone by equilibrium dialysis, a test which is only available in a few specialized endocrinology labs. References: In men with signs and symptoms of possible hypogonadism

2019 Clinical Correlations

2. Testosterone replacement in menopause

Testosterone replacement in menopause BRITISH MENOPAUSE SOCIETY T ool for clinicians Information for GPs and other health professionals 1 of 4 1 How much and where does it come from? Testosterone is an important female hormone. Healthy young women produce approximately 100 – 400 mcg per day. This represents three to four times the amount of estrogen produced by the ovaries. Approximately half of endogenous testosterone and precursors are derived from the ovaries e.g. androstenedione and half (...) from the adrenal glands e.g. dehydroepiandrosterone. Some of the effects are direct and some due to peripheral conversion to estrogen by aromatase. Testosterone levels naturally decline throughout a woman’s lifespan. Loss of testosterone is particularly profound after iatrogenic i.e. surgical and medical menopause and premature ovarian insufficiency when testosterone production decreases by more than 50%. 2 What is its role in women? Testosterone contributes to libido, sexual arousal and orgasm

2019 British Menopause Society

3. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data

Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data The benefits and risks of testosterone treatment for women with diminished sexual wellbeing remain controversial. We did a systematic review and meta-analysis to assess potential benefits and risks of testosterone for women.We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science for blinded, randomised controlled trials (...) of testosterone treatment of at least 12 weeks' duration completed between Jan 1, 1990, and Dec 10, 2018. We also searched drug registration applications to the European Medicine Agency and the US Food and Drug Administration to identify any unpublished data. Primary outcomes were the effects of testosterone on sexual function, cardiometabolic variables, cognitive measures, and musculoskeletal health. This study is registered with the International Prospective Register of Systematic Reviews (PROSPERO), number

2019 EvidenceUpdates

4. Testosterone Replacement Guidelines

Testosterone Replacement Guidelines Page | 1 BSPED Guideline: Testosterone Therapy in Infancy and Adolescence Initial authors: R El-Khairi, N Shaw, EC Crowne (November 2016) Revision: A Chinoy, EC Crowne, M Skae (January 2018) Scope This guideline is intended for general paediatricians and paediatric endocrinologists who are regularly managing boys with absent/delayed puberty requiring exogenous testosterone therapy. This includes boys with hypogonadotrophic hypogonadism (HH) of various (...) aetiology, androgen deficiency secondary to testicular failure (hypergonadotrophic hypogonadism) of various aetiology, and constitutional delay of growth and puberty (CDGP). The aim of testosterone replacement therapy is to mimic the normal pattern of puberty and mimic requirements at different stages of pubertal development 1 . This guideline aims to provide the clinician with testosterone dosing regimens for pubertal induction, progression and post-pubertal maintenance, as well as for penile growth

2019 British Society for Paediatric Endocrinology and Diabetes

5. Testosterone (Testavan) - testosterone replacement therapy for adult male hypogonadism

Testosterone (Testavan) - testosterone replacement therapy for adult male hypogonadism Published 08 April 2019 1 www.scottishmedicines.org.uk Product update SMC2152 testosterone 20mg/g transdermal gel (Testavan®) Ferring Pharmaceuticals Ltd 8 March 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following (...) an abbreviated submission testosterone gel (Testavan ® ) is accepted for restricted use within NHSScotland. Indication under review: testosterone replacement therapy for adult male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests. SMC restriction: patients requiring a transdermal delivery system. Testosterone (Testavan ® ) is bioequivalent to another testosterone transdermal preparation and costs less. Advice context: No part of this advice may be used

2019 Scottish Medicines Consortium

6. Association of genetically predicted testosterone with thromboembolism, heart failure, and myocardial infarction: mendelian randomisation study in UK Biobank. (PubMed)

Association of genetically predicted testosterone with thromboembolism, heart failure, and myocardial infarction: mendelian randomisation study in UK Biobank. To determine whether endogenous testosterone has a causal role in thromboembolism, heart failure, and myocardial infarction.Two sample mendelian randomisation study using genetic variants as instrumental variables, randomly allocated at conception, to infer causality as additional randomised evidence.Reduction by Dutasteride of Prostate (...) participants, 13 691 had thromboembolism (6208 men, 7483 women), 1688 had heart failure (1186, 502), and 12 882 had myocardial infarction (10 136, 2746). In men, endogenous testosterone genetically predicted by variants in the JMJD1C gene region was positively associated with thromboembolism (odds ratio per unit increase in log transformed testosterone (nmol/L) 2.09, 95% confidence interval 1.27 to 3.46) and heart failure (7.81, 2.56 to 23.8), but not myocardial infarction (1.17, 0.78 to 1.75

Full Text available with Trip Pro

2019 BMJ

7. Testosterone Testing - Protocol

Testosterone Testing - Protocol Testosterone Testing - Protocol - Province of British Columbia theme_3_collection theme_3_frontend theme_3_collection theme_3_frontend Birth, Adoption, Death, Marriage & Divorce theme_1_collection theme_1_frontend theme_1_collection theme_1_frontend British Columbians & Our Governments theme_data_collection data_frontend theme_data_collection data_frontend Data theme_5_collection theme_5_frontend theme_5_collection theme_5_frontend Driving & Transportation (...) & Culture theme_8_collection theme_8_frontend theme_8_collection theme_8_frontend Taxes & Tax Credits theme_14_collection theme_14_frontend theme_14_collection theme_14_frontend Tourism & Immigration Search default_collection default_frontend Section Navigation Testosterone Testing - Protocol Effective Date: September 19, 2018 Recommendations and Topics Scope This protocol reviews the appropriate use of serum testosterone testing in men and women aged ≥ 19 years. This document is intended to direct

2019 Clinical Practice Guidelines and Protocols in British Columbia

8. Effect of testosterone supplementation in chronic patients on sarcopenic components: a systematic review and meta-analysis

Effect of testosterone supplementation in chronic patients on sarcopenic components: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2019 PROSPERO

9. Testosterone and its derivatives treatment for frailty in elderly people: a systematic review and meta-analysis

Testosterone and its derivatives treatment for frailty in elderly people: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

10. Does Suppression Levels of Testosterone Have an Impact in The Craniofacial Growth? A Systematic Review in Animal Studies

Does Suppression Levels of Testosterone Have an Impact in The Craniofacial Growth? A Systematic Review in Animal Studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

11. Effect of testosterone treatment on cardiovascular events in men

Effect of testosterone treatment on cardiovascular events in men Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

12. Feedback on LH in Testosterone-Clamped Men Depends on the Mode of Testosterone Administration and Body Composition. (PubMed)

Feedback on LH in Testosterone-Clamped Men Depends on the Mode of Testosterone Administration and Body Composition. Quantitative studies of the short-term feedback of testosterone (T) on luteinizing hormone (LH) secretion in healthy men are relatively rare. Such studies require the shutting down of endogenous T secretion and the imposition of experimentally controlled IV T addback.To evaluate whether pulsatile and continuous T delivery confers equivalent negative feedback on LH secretion.This

Full Text available with Trip Pro

2019 Journal of the Endocrine Society Controlled trial quality: uncertain

13. Effect of fenugreek seed extract supplement on testosterone levels in males: a meta-analysis of clinical trials

Effect of fenugreek seed extract supplement on testosterone levels in males: a meta-analysis of clinical trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

14. Oncological safety of testosterone replacement therapy in prostate cancer survivors with the history of definitive therapy: systematic literature review and meta-analysis

Oncological safety of testosterone replacement therapy in prostate cancer survivors with the history of definitive therapy: systematic literature review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

15. The effect of testosterone replacement therapy on prostate specific antigen (PSA) levels: a systematic review and meta-analysis

The effect of testosterone replacement therapy on prostate specific antigen (PSA) levels: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

16. Should we combine exercise with an anabolic agent to get a better prognosis in skeletal muscle mass loss conditions? A systematic review of testosterone-based interventions

Should we combine exercise with an anabolic agent to get a better prognosis in skeletal muscle mass loss conditions? A systematic review of testosterone-based interventions Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

17. Effect of atorvastatin on testosterone levels [Cochrane protocol]

Effect of atorvastatin on testosterone levels [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

18. Effect of testosterone supplementation on muscle strength, muscle mass and physical performance in middle-age and elderly men: a systematic review and meta-analysis

Effect of testosterone supplementation on muscle strength, muscle mass and physical performance in middle-age and elderly men: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

19. The effect of long-acting vs short-acting testosterone therapy on gonadotropins in hypogonadal men

The effect of long-acting vs short-acting testosterone therapy on gonadotropins in hypogonadal men Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

20. Androgens In Men Study: a systematic review for IPD meta-analyses investigating associations of testosterone with health outcomes in men

Androgens In Men Study: a systematic review for IPD meta-analyses investigating associations of testosterone with health outcomes in men Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO